Acarix Ab (publ) logo

Acarix Ab (publ)(OTC) ACIXF

Market Cap$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-26%
5 YearN/A
1 Year-33%
1 Month-7%
$0.03
+0.00%
+0.00Today
Acarix Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 0.032026-10-01
Acarix Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+13.14%USD 0.022026-09-22
1 month-7.14%USD 0.032026-08-07
3 month-9.97%USD 0.032026-06-29
Year to date-14.61%USD 0.032025-12-26
1 year-32.99%USD 0.042025-10-01
3 year-5.41%USD 0.032023-06-16
Since inception-25.71%USD 0.042022-12-07

Acarix Ab (publ) Financials at a Glance

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 9.19M

Net Income (TTM)

-SEK 39.24M

EPS (TTM)

-$0.00

P/E Ratio

-7.22

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.03

Volume

19,000

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.02 - $0.04

Estimated Earnings Date

Nov 5, 2026

ACIXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acarix Ab (publ)

Acarix AB (publ) is a medical technology company focused on developing AI-powered diagnostic tools for the assessment of coronary artery disease (CAD). The company operates both in Sweden and internationally, with its flagship product, the CADScor System, designed for immediate patient evaluation.

Products and Services
  • CADScor System for rapid CAD assessment
  • AI-driven diagnostic support tools
  • International deployment of medical technology solutions
Growth Outlook
  • Strong demand for CAD diagnostics in healthcare markets
  • Expansion plans targeting international markets
  • Innovative technology positioning for future growth
Financial Highlights
  • Q2 2026 revenue of 2,288,247 SEK, showing consistent sales
  • Cash and cash equivalents of 28,635,882 SEK as of June 2026
  • Current ratio of 10.67 indicates strong liquidity position
Acarix AB (publ) has established itself as a key player in the medical device industry, particularly in the realm of coronary artery disease diagnostics. The CADScor System utilizes advanced acoustic measurements and AI algorithms, providing healthcare professionals with immediate insights into patient conditions. This innovative approach not only enhances diagnostic accuracy but also streamlines patient care processes. The growth outlook for Acarix is promising, driven by increasing global demand for effective CAD diagnostics. The company is actively pursuing expansion into international markets, which could significantly enhance its revenue potential. Furthermore, the innovative nature of its technology positions Acarix favorably for future advancements and market opportunities. Financially, Acarix has demonstrated resilience, with a notable revenue figure reported in the most recent quarter. The company's liquidity is robust, as evidenced by its substantial cash reserves, which provide a solid foundation for ongoing operations and potential investments in growth initiatives. The current ratio indicates a strong ability to meet short-term obligations, further enhancing investor confidence in the company's financial health.
AI Generated • Sep 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

8

CEO

Aamir Mahmood, MBA

Website

www.acarix.com

Headquarters

Malmö, SN 215 32, SE

ACIXF Financials

Key Financial Metrics (TTM)

Gross Margin

55.82%

Operating Margin

-421.80%

Net Income Margin

-426.99%

Return on Equity

-100.09%

Return on Capital

-125.78%

Return on Assets

-82.49%

Earnings Yield

-13.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24B

Volume

19.00K

Avg. Volume

11.71K

Financials (TTM)

Gross Profit

SEK 5.13M

Operating Income

-SEK 38.76M

EBITDA

-SEK 34.75M

Operating Cash Flow

-SEK 34.63M

Capital Expenditure

SEK 10.32M

Free Cash Flow

-SEK 23.19M

Cash & ST Invst.

SEK 28.64M

Total Debt

SEK 0.00

Acarix Ab (publ) Performance Analysis

Acarix Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 575,30331.4%
20232023-12-31SEK 587,8892.2%
20242024-12-31SEK 586,603-0.2%
20252025-12-31SEK 750,54727.9%
Acarix Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30106.1%
Q42025-12-31-9.1%
Q12026-03-3113.1%
Q22026-06-30-5.3%
Acarix Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.03-22.7%
20232023-12-31SEK -0.02-43.6%
20242024-12-31SEK -0.01-55.8%
20252025-12-31SEK -0.00-35.3%
Acarix Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3012.3%
Q42025-12-31-1.0%
Q12026-03-311.0%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 2.29M

+100.7%

Gross Profit

SEK 922.04K

-13.7%

Gross Margin

40.29%

N/A

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.03M

N/A

Employees

8

N/A

Net Income

-SEK 9.40M

+26.9%

EBITDA

-SEK 8.24M

+31.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 28.64M

-11.2%

Total Debt

SEK 0.00

N/A

Accounts Receivable

SEK 7.21M

+46.3%

Inventory

SEK 6.07M

-16.5%

Long Term Debt

SEK 0.00

N/A

Short Term Debt

SEK 0.00

N/A

Return on Assets

-82.49%

N/A

Return on Invested Capital

-88.87%

N/A

Free Cash Flow

SEK 0.00

+100.0%

Operating Cash Flow

-SEK 11.73M

+7.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ACUTAccustem Sciences Inc.
$0.15+0.00%
ABTIAlterola Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About ACIXF

What is the current price of Acarix Ab (publ)?

Acarix Ab (publ) is trading at $0.03 per share.

What is the 52-week range for Acarix Ab (publ)?

Over the past 52 weeks, Acarix Ab (publ) has traded between $0.02 and $0.04.

How much debt does Acarix Ab (publ) have?

As of the most recent reporting period, Acarix Ab (publ) reported total debt of SEK 0.00.

How much cash does Acarix Ab (publ) have on hand?

Acarix Ab (publ) reported SEK 2.98M in cash and cash equivalents in its most recent financial results.

What is Acarix Ab (publ)’s dividend yield?

Acarix Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services